Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc dextran 500 + patent blue V
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Subcutaneous, Peritumoral
01
Overview
A combination of a radiopharmaceutical (99mTc dextran 500) and a vital blue dye (patent blue V) used for sentinel lymph node detection and mapping, particularly in breast cancer surgery. The dual-tracer technique enhances visualization and identification of sentinel lymph nodes during surgical procedures.
02
Targets
MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on 99mTc dextran 500 + patent blue V.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc dextran 500 + patent blue V.